Morgan Stanley Upgrades CAVA Stocks to Overweight, Raises Target to $90

Morgan Stanley upgraded Mediterranean fast-casual restaurant chain CAVA (NYSE: CAVA) from Equal Weight to Overweight and raised its target price from $86 to $90. Brian Harbour, Morgan Stanley analyst, stated that CAVA possesses the strongest fundamentals in the restaurant industry, citing robust key performance indicators including traffic growth, new store efficiency, and profitability visibility. The upgrade comes despite CAVA trading at an enterprise value-to-EBITDA multiple exceeding 44x, following a 21% stock decline over the past three months amid same-store sales growth deceleration and valuation concerns.

Morgan Stanley Analyst Cites Strong Fundamentals Despite High Valuation

According to CNBC on the 15th (local time), Brian Harbour, Morgan Stanley analyst, stated that CAVA is the company with the strongest fundamentals in the restaurant industry. He evaluated that key performance indicators such as traffic growth, new store efficiency, and profitability visibility are very solid.

CAVA currently faces criticism that it is not a cheap stock, with its enterprise value-to-EBITDA multiple exceeding 44x. However, Harbour analyzed that CAVA's innovative menu development and high customer loyalty are strong qualitative factors sufficient to quell overvaluation concerns.

CAVA Stocks Decline 21% Amid Same-Store Sales Slowdown

CAVA experienced a deceleration in same-store sales growth over the past three months. As a result, the stock underwent approximately 21% correction and became engulfed in overvaluation concerns.

Analyst Forecasts Q2 and Full-Year Guidance Achievement

Harbour forecasted that CAVA will smoothly achieve its second-quarter results and full-year guidance.

FAQ

What did Morgan Stanley do regarding CAVA stocks on the 15th?

Morgan Stanley upgraded CAVA from Equal Weight to Overweight and raised its target price from $86 to $90 on the 15th (local time).

Why did CAVA stocks decline 21% over the past three months?

CAVA stocks declined approximately 21% due to a deceleration in same-store sales growth over the past three months, leading to overvaluation concerns despite trading at an enterprise value-to-EBITDA multiple exceeding 44x.